Palisade Bio (NASDAQ: PALI) announced that data from its lead program, PALI-2108, will be presented as a poster at Digestive Disease Week 2026 on May 5, 2026. The poster covers translational Phase 1 findings showing clinical, histologic and biomarker improvement in ulcerative colitis.
Poster session: Mechanisms of IBD Therapeutics; time: May 5, 12:30–1:30 PM CDT; location: Poster Hall, Level 3, Hall F2, McCormick Place. Management and Clinical Advisory Board members will attend and meet with qualified investors.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – PALI
-0.43%
1 alert
-0.43%News Effect
On the day this news was published, PALI declined 0.43%, reflecting a mild negative market reaction.
Shares issued:1,536,885 sharesProceeds:$3.0 millionIssue price:$1.952 per share+5 more
8 metrics
Shares issued1,536,885 sharesPrivate sale to Iterative Health affiliate (8-K dated 2026-04-02)
Proceeds$3.0 millionTotal consideration for private share sale to Iterative Health affiliate
Issue price$1.952 per sharePrice in Iterative Health private transaction, matching 5-day average
RSU grant787,000 RSUsRestricted stock units granted to Chief Medical Officer on Feb 9, 2026
Shelf block988,872 sharesShares listed in S-3 shelf registration filed Aug 15, 2025
Ownership percentage10.24%Portion of disclosed share counts covered by shelf-listed block
Poster session timeMay 5, 2026, 12:30–1:30 PM CDTDDW 2026 poster presentation slot for PALI-2108 data
Study phasePhase 1Translational findings in ulcerative colitis highlighted in DDW 2026 poster title
Market Reality Check
Price:$2.08Vol:Volume 5,783,750 vs 20-da...
normal vol
$2.08Last Close
VolumeVolume 5,783,750 vs 20-day average 4,366,808 (1.32x), indicating elevated trading ahead of the DDW 2026 poster.normal
TechnicalPrice $2.34 is above the $1.52 200-day MA and 11.36% below the $2.64 52-week high.
Peers on Argus
PALI gained 13.59% while scanner data shows 4 peers moving in the same general m...
1 Up4 Down
PALI gained 13.59% while scanner data shows 4 peers moving in the same general momentum cohort (median -3.9%) and 1 peer up 6.07%, pointing to mixed but notable sector-wide activity.
Common CatalystScanner commentary flags broader biotechnology sector dynamics without specific peer news catalysts.
Appointment of global IBD precision medicine expert to Clinical Advisory Board.
Pattern Detected
Recent history shows mixed alignment: several positive clinical and corporate updates have seen both modest gains and selloffs, indicating that news flow has not consistently driven upside.
Recent Company History
Over the last few months, Palisade Bio has focused on advancing PALI-2108 through clinical and investor visibility milestones. Positive Phase 1b data in fibrostenotic Crohn’s disease on Mar 30, 2026 and translational findings at ECCO 2026 on Feb 23, 2026 highlighted rapid, colon‑targeted activity. Management also expanded its Clinical Advisory Board and participated in multiple investor conferences. Today’s DDW 2026 poster selection continues this pattern of showcasing PALI-2108 data at major gastroenterology meetings.
Regulatory & Risk Context
Active S-3 Shelf
Shelf Active
Active S-3 Shelf Registration
2025-08-15
The company has an active S-3 shelf registration filed on Aug 15, 2025, listing a block of 988,872 shares (representing 10.24% of disclosed share counts). Estimated offering expenses total $49,000. The shelf has seen at least one usage via a 424B4 filing on Oct 2, 2025, and is currently marked as not effective in the context data.
Market Pulse Summary
This announcement highlights additional visibility for PALI-2108 through a DDW 2026 poster focused o...
Analysis
This announcement highlights additional visibility for PALI-2108 through a DDW 2026 poster focused on Phase 1 translational findings in ulcerative colitis. It builds on earlier ECCO data and conference participation, reinforcing the company’s emphasis on gastroenterology audiences and expert engagement. Investors may watch for the full poster content, future Phase 2 progress, and any further use of the S-3 shelf or equity transactions disclosed in recent regulatory filings.
Key Terms
pde4 inhibitor, prodrugs, terminal ileum, ulcerative colitis, +4 more
8 terms
pde4 inhibitormedical
"oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum"
A PDE4 inhibitor is a drug that blocks an enzyme (PDE4) involved in turning off certain cell signals linked to inflammation and brain activity; blocking it lets those signals persist and can reduce inflammation or alter nerve-cell behavior. Investors care because this drug class underlies treatments for conditions like chronic inflammatory and neurological disorders, so clinical trial results, regulatory decisions, or patent news can strongly affect a company’s drug pipeline value and stock outlook.
prodrugsmedical
"oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum"
Prodrugs are medicine compounds designed to be inactive or less active when taken and then converted inside the body into the active drug. Like a packaged meal that needs cooking before it can be eaten, they can improve how a medicine is absorbed, reduce side effects, or extend patent and dosing advantages; investors watch prodrugs because these properties affect regulatory approval, market competitiveness, development costs, and potential revenue.
terminal ileummedical
"targeted delivery to the terminal ileum and colon"
The terminal ileum is the final segment of the small intestine that connects to the large intestine; think of it as the doorway between two rooms of the digestive tract where nutrients are absorbed and waste moves on. It matters to investors because many gastrointestinal diseases, targeted drugs, diagnostic tests, and surgical procedures focus on this specific site, so outcomes or regulatory news about treatments affecting the terminal ileum can materially influence clinical trial results, approvals, and a company’s financial prospects.
ulcerative colitismedical
"Improvement in Ulcerative Colitis: Translational Findings from a Phase 1 Study"
A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.
biomarkermedical
"Demonstrates Rapid Clinical, Histologic and Biomarker Improvement in Ulcerative Colitis"
A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.
histologicmedical
"Demonstrates Rapid Clinical, Histologic and Biomarker Improvement in Ulcerative Colitis"
Relating to the microscopic structure of tissue, 'histologic' describes observations made by examining thin slices of cells and tissue under a microscope. For investors, histologic findings matter because they help determine how a disease is classified, how well a treatment works at the tissue level, and whether regulators or doctors will accept a therapy—think of it like inspecting the weave of fabric to judge quality and suitability for use.
phase 1 studymedical
"Translational Findings from a Phase 1 Study"
A phase 1 study is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, side effects and the right dose rather than proving effectiveness. Think of it as a short, closely monitored test drive that checks how the body tolerates the treatment and how it behaves inside the body; results matter to investors because positive safety and dosing data are needed before larger, more value-driving trials can begin.
clinical advisory boardtechnical
"alongside members of its Clinical Advisory Board (CAB), further reinforcing its engagement"
A clinical advisory board is a group of independent medical and scientific experts a company consults to guide clinical development, trial design, regulatory strategy and product use. Like a navigation team advising a ship’s captain, they bring real‑world experience and credibility that can speed development, reduce regulatory and clinical risk, and influence investor confidence by signaling that the science and path to market are being thoughtfully managed.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT
Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week® (DDW) 2026, taking place May 2–5, 2026 in Chicago.
The Company will be in attendance alongside members of its Clinical Advisory Board (CAB), further reinforcing its engagement with leading experts in inflammatory bowel disease as it advances PALI-2108 toward the clinic.
Poster Presentation details are as follows: Session Type: Abstract Poster Session Title: Mechanisms of IBD Therapeutics Title:Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic and Biomarker Improvement in Ulcerative Colitis: Translational Findings from a Phase 1 Study Session Date & Time: May 5, 2026 from 12:30 PM to 1:30 PM CDT Location: Poster Hall, Level 3, Hall F2 (McCormick Place)
Management will be available to participate in one-on-one meetings with qualified members of the investor community.
Digestive Disease Week is a leading forum for experts in the field of gastroenterology bringing together clinicians, researchers, and pharmaceutical leaders to discuss the latest advancements in treating digestive diseases. For more information about Digestive Disease Week please visit the conference website.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing next-generation oral PDE4 inhibitor prodrugs designed for gut-targeted delivery and selective bioactivation in the ileum and colon, with the goal to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to initiate localized PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug.
Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. For more information, please go to www.palisadebio.com.
What will Palisade Bio (PALI) present at Digestive Disease Week 2026 on May 5, 2026?
Palisade will present a poster on PALI-2108 showing Phase 1 translational findings in ulcerative colitis. According to Palisade, the poster reports rapid clinical, histologic and biomarker improvements and is scheduled May 5, 12:30–1:30 PM CDT in Poster Hall F2.
Where and when is the PALI-2108 poster session scheduled at DDW 2026?
The poster is scheduled May 5, 2026 from 12:30–1:30 PM CDT in Poster Hall, Level 3, Hall F2 at McCormick Place. According to Palisade, it appears in the "Mechanisms of IBD Therapeutics" abstract poster session.
What clinical program is Palisade Bio (PALI) highlighting at DDW 2026?
Palisade is highlighting its lead program, PALI-2108, a gut-targeted PDE4 inhibitor prodrug for ulcerative colitis. According to Palisade, the poster summarizes translational Phase 1 data with clinical, histologic and biomarker improvement signals.
Will Palisade management meet with investors at Digestive Disease Week 2026?
Yes. Management said they will be available for one-on-one meetings with qualified members of the investor community during DDW. According to Palisade, company leadership and Clinical Advisory Board members will attend and host meetings by request.
How does the DDW 2026 presentation affect Palisade Bio's (PALI) clinical visibility?
The DDW poster increases visibility among gastroenterology experts and potential collaborators. According to Palisade, presenting Phase 1 translational findings at a leading gastroenterology forum can support scientific engagement and clinical interest in PALI-2108.
